U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C18H18N4O3S2.CH4O3S.H2O
Molecular Weight 516.611
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of Pritelivir mesylate monohydrate

SMILES

O.CS(O)(=O)=O.CN(C(=O)CC1=CC=C(C=C1)C2=NC=CC=C2)C3=NC(C)=C(S3)S(N)(=O)=O

InChI

InChIKey=QPIDAZSAUYNBAC-UHFFFAOYSA-N
InChI=1S/C18H18N4O3S2.CH4O3S.H2O/c1-12-17(27(19,24)25)26-18(21-12)22(2)16(23)11-13-6-8-14(9-7-13)15-5-3-4-10-20-15;1-5(2,3)4;/h3-10H,11H2,1-2H3,(H2,19,24,25);1H3,(H,2,3,4);1H2

HIDE SMILES / InChI

Molecular Formula CH4O3S
Molecular Weight 96.106
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula H2O
Molecular Weight 18.0153
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C18H18N4O3S2
Molecular Weight 402.491
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Pritelivir is a thiazolylamide derivative patented by German multinational pharmaceutical and life sciences company Bayer A.-G. as helicase-primase enzyme inhibitor that is active against herpes simplex virus types 1 and 2 (HSV-1 and HSV-2). In preclinical Pritelivir was shown to be active when treatment was delayed to 72 h post viral inoculation and appeared to synergistically inhibit mortality in this model in combination with acyclovir. Pritelivir could be an alternative therapeutic agent for patients infected with acyclovir-resistant strains. Phase II clinical trials currently are ongoing.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
30.0 nM [IC50]
PubMed

PubMed

TitleDatePubMed
Baseline sensitivity of HSV-1 and HSV-2 clinical isolates and defined acyclovir-resistant strains to the helicase-primase inhibitor pritelivir.
2013-11
ASP2151, a novel helicase-primase inhibitor, possesses antiviral activity against varicella-zoster virus and herpes simplex virus types 1 and 2.
2010-08
Potent in vivo antiviral activity of the herpes simplex virus primase-helicase inhibitor BAY 57-1293.
2002-06
New helicase-primase inhibitors as drug candidates for the treatment of herpes simplex disease.
2002-04
Patents

Sample Use Guides

100mg/day (400mg loading dose on day 1) over 4 weeks
Route of Administration: Oral
Substance Class Chemical
Created
by admin
on Wed Apr 02 19:13:50 GMT 2025
Edited
by admin
on Wed Apr 02 19:13:50 GMT 2025
Record UNII
7EX4CZ4HYG
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
Pritelivir mesylate hydrate
Preferred Name English
Pritelivir mesylate monohydrate
Common Name English
Benzeneacetamide, N-[5-(aminosulfonyl)-4-methyl-2-thiazolyl]-N-methyl-4-(2-pyridinyl)-, methanesulfonate, hydrate (1:1:1)
Systematic Name English
Code System Code Type Description
CAS
1428321-10-1
Created by admin on Wed Apr 02 19:13:50 GMT 2025 , Edited by admin on Wed Apr 02 19:13:50 GMT 2025
PRIMARY
SMS_ID
300000048293
Created by admin on Wed Apr 02 19:13:50 GMT 2025 , Edited by admin on Wed Apr 02 19:13:50 GMT 2025
PRIMARY
FDA UNII
7EX4CZ4HYG
Created by admin on Wed Apr 02 19:13:50 GMT 2025 , Edited by admin on Wed Apr 02 19:13:50 GMT 2025
PRIMARY
PUBCHEM
71515453
Created by admin on Wed Apr 02 19:13:50 GMT 2025 , Edited by admin on Wed Apr 02 19:13:50 GMT 2025
PRIMARY
CAS
910864-60-7
Created by admin on Wed Apr 02 19:13:50 GMT 2025 , Edited by admin on Wed Apr 02 19:13:50 GMT 2025
NON-SPECIFIC STOICHIOMETRY
Related Record Type Details
PARENT -> SALT/SOLVATE
ANHYDROUS->SOLVATE
Related Record Type Details
ACTIVE MOIETY